Glutamate carboxypeptidase II (GCP II) catalyzes the extracellular hydrolysis of the neuromodulator N-acetyl-aspartylglutamate to N-acetyl-aspartate and glutamate. GCP II also hydrolyzes ␥-glutamyl bonds in folylpolyglutamate. The predicted amino acid sequence of GCP II displays similarities to aminopeptidases from Streptomyces griseus and Vibrio proteolyticus, whose crystal structures have been determined. These aminopeptidases are cocatalytic zinc metallopeptidases belonging to the peptidase family M28. Specific zinc and substrate ligands have been proposed in GCP II based on the amino acid sequence alignment to these M28 family members. In the present study, site-directed mutagenesis has been used to test the assignment of these putative ligands in human GCP II. Substitutions to the five putative zinc ligands resulted in severely reduced enzyme activity, although mutant protein was expressed as demonstrated by immunoblot analysis. In addition, substitutions of amino acids near the putative zinc ligands have identified other specific residues important for enzyme structure and/or function. Substitutions to putative substrate ligands were less perturbing, and increases in K m were observed for substitutions that introduced a large charge perturbation (e.g., Lys to Glu). The results from substitutions at the proposed zinc and substrate ligands are consistent with the assignment of these residues and suggest that GCP II has a three-dimensional structure similar to other members of the peptidase family M28.
II. Substitutions to the five putative zinc ligands resulted in severely reduced enzyme activity, although mutant protein was expressed as demonstrated by immunoblot analysis. In addition, substitutions of amino acids near the putative zinc ligands have identified other specific residues important for enzyme structure and/or function. Substitutions to putative substrate ligands were less perturbing, and increases in K m were observed for substitutions that introduced a large charge perturbation (e.g., Lys to Glu). The results from substitutions at the proposed zinc and substrate ligands are consistent with the assignment of these residues and suggest that GCP II has a three-dimensional structure similar to other members of the peptidase family M28. (NAAG) to N-acetyl-aspartate and glutamate in the extracellular space (Robinson et al., 1987; Stauch et al., 1989; Serval et al., 1990; Slusher et al., 1990) . NAAG inhibits glutamate's activation of the N-methyl-D-aspartate ionotropic receptor (Sekiguchi et al., 1989; Puttfarcken et al., 1993; Burlina et al., 1994; Grunze et al., 1996) and is an agonist at the metabotropic glutamate receptor mGluR3 . GCP II terminates the action of NAAG and generates extrasynaptic glutamate in the brain. Inhibition of GCP II by 2-(phosphonomethyl)pentanedioic acid (PMPA), has been shown to be effective in preventing neuronal cell death in models of ischemia (Harukuni et al., 1997) . GCP II also hydrolyzes ␥-glutamyl linkages in pteroylpolyglutamate (Pinto et al., 1996) . Conversion of pteroylpolyglutamate to pteroylmono-glutamate is necessary for intestinal absorption of folic acid.
Glutamate carboxypeptidase II (GCP II) hydrolyzes the abundant neuropeptide N-acetyl-aspartylglutamate
GCP II is also expressed in selected sites outside the brain including nonmyelinating Schwann cells and the neuromuscular junction, small intestine, kidney, and prostate (Slusher et al., 1992; Berger et al., 1995a,b; Troyer et al., 1995a) . At some of these peripheral sites, GCP II may act on substrates other than NAAG. The name glutamate carboxypeptidase II (EC 3.4.17.21 ) has been recently assigned; the enzyme has previously been called N-acetyl-␣-linked acidic dipeptidase or NAALADase and prostate-specific membrane antigen or PSM. Molecular characterizations of rat, pig, and human forms of GCP II have been described (Israeli et al., 1993; Carter et al., 1996; Bzdega et al., 1997; Halsted et al., 1998; Luthi-Carter et al., 1998) . GCP II is a class II membrane glycoprotein with an apparent molecular mass of 94 to 100 kDa. Class II membrane proteins have a short cytoplasmic amino terminus, a single membrane-spanning domain, and a large extracellular domain (Fig. 1) . A model for human GCP II has recently been proposed by Rawlings and Barrett (1997) based on a region of similarity to the peptidase family M28 comprised of cocatalytic metallopeptidases. The catalytic domain of GCP II ( Fig.  1) has been identified by sequence similarities to low molecular weight aminopeptidases from Streptomyces griseus and Vibrio proteolyticus (also known as Aeromonas proteolytica). The X-ray crystal structures have been determined for the Streptomyces and Vibrio aminopeptidases at 1.75-Å and 1.8-Å resolution, respectively (Chevrier et al., 1994; Greenblatt et al., 1997) . These peptidases have a binuclear Zn ϩϩ center at the active site in which the two zinc ions share a bridging carboxylate ligand. In addition, the structure of carboxypeptidase G 2 has been determined at 2.5-Å resolution and has a central topology quite similar to the Vibrio aminopeptidase, even though no significant amino acid sequence identity exists (Rowsell et al., 1997) . Carboxypeptidase G 2 hydrolyzes the ␣-linked glutamate from folic acid. The binuclear zinc-binding sites found in carboxypeptidase G 2 and the Vibrio aminopeptidase are highly similar in structure and ligand environment (Table 1) .
To test amino acid assignments, putative ligands for Zn ϩϩ in GCP II have been targeted for amino acid substitution based on the alignment of the amino acid sequence to the Streptomyces and Vibrio aminopeptidases. The five putative Zn ϩϩ ligands and their positions in GCP II are: His-377, Asp-387, Glu-425, Asp-453, and His-553, where Asp-387 is predicted to be the bridging ligand (Table 1) . In contrast to both structural and catalytic mono-zinc sites, carboxylate oxygen coordination predominates in binuclear zinc sites (Vallee and Auld, 1993) .
The crystal structure of the Vibrio aminopeptidase shows 10 residues lining a hydrophobic specificity pocket implicated in substrate binding (Chevrier et al., 1994) . In the amino acid sequence alignment, Rawlings and Barrett (1997) noted that four of the residues that line the specificity pocket of the Vibrio enzyme are substituted by positively charged residues (i.e., Arg-463, Lys-499, Arg-536, and Lys-545), which may account in part for substrate specificity in GCP II (Table 2) . These and some of the other 10 predicted substrate ligands, a subset of which are next to putative zinc ligands, have been targeted for amino acid substitution (Tables 1 and 2 ).
Materials and Methods
Site-Directed Mutagenesis. The cDNA for human GCP II has been subcloned into the mammalian expression vector, pcDNA3 (Invitrogen Corporation, Carlsbad, CA). Single-stranded template was used in an in vitro mutagenesis reaction according to Kunkel et al. (1991) . When possible, restriction sites were designed into or out of the mutation site to facilitate screening. Mutations were confirmed by DNA sequencing.
Radioenzymatic Assay of Enzyme Activity. To test for alterations in function of the encoded proteins, plasmids containing the confirmed mutations were transiently transfected into the prostate cancer cell line PC3 (American Type Culture Collection, Rockville, MD), which does not express endogenous GCP II activity or protein (Carter et al., 1996) . Transfections were carried out following a calcium phosphate method in 50 mM HEPES, pH 7.05 (Graham and van der Eb, 1973) . After incubation for 48 h, cells were harvested at 4°C and sonicated in the presence of 50 mM Tris, pH 7.4, 0.5% Triton X-100 in high-pressure liquid chromatography grade H 2 O. Cell lysates were then incubated in the presence of the radiolabeled substrate N-acetyl-L-aspartyl-L- [3, H]glutamate (NEN Life Science Products, Boston, MA). Products were separated from intact substrate using disposable anion exchange columns and L- [3,4- 3 H]glutamate measured by scintillation spectrometry as described in a study by Robinson et al. (1987) . Enzymatic activity of GCP II in 2 g of total protein from the cell lysate was assayed in a final volume of 250 l using 30 nM N-acetyl-L-aspartyl-L- [3, H]glutamate in 50 mM Tris, pH 7.4, at 37°C, 0.1% Triton X-100, 150 M potassium phosphate, and 1 mM CoCl 2 (Robinson et al., 1987) . Total protein was assayed using the bicinchoninic acid assay (Pierce, Rockford, IL). To test for metal ion dependence of mutant enzyme activity, activity was recovered by the addition of Co ϩϩ or Zn ϩϩ in the presence of EDTA (Robinson et al., 1987) . Because all transfects were expressed in the same cell system, it is assumed that differences in kinetic characteristics reflect primarily the transfected species.
Kinetic Analysis. For those mutants that showed activity, Michaelis-Menten (saturation) kinetics were performed. The K m and V max parameters were determined by a nonlinear least-squares fit of the initial velocity versus substrate concentration plot using Prism software (GraphPad, San Diego, CA) where the error in these parameters is represented by the 95% confidence interval. At each substrate concentration, three time points were taken either at 15, 30, and 45 min for wild type or up to 120, 180, and 240 min for mutants within the linear range of the assay. Background counts from the coelution of intact substrate were subtracted from each point by including a sample without enzyme. The concentration of the labeled substrate [ 3 H]NAAG was kept constant at 30 nM, whereas the concentration of unlabeled substrate was varied from 100 to 3000 nM. The initial velocity, v (in femtomoles per minute), at a given substrate concentration was determined from the slope of the linear plot of product versus time where the error in the initial velocity is represented by the S.E.M. of the 95% confidence interval from the linear regression of the slope. To compare changes in V max between mutant and wild-type enzymes, the V max parameter has been normalized by the ratio of wild-type to mutant protein from the relative intensity of the signal measured from an immunoblot (see below).
Inhibitor Analysis. Activity of selected mutants was measured in the presence of varying concentrations of inhibitors in a volume of 125 l using 2 g of total protein, 1 mM CoCl 2 , and 10 nM [ 3 H]NAAG. PMPA was a gift from Dr. Barbara Slusher (Guilford Pharmaceuticals, Baltimore, MD). Pteroylpenta-␥-glutamate was purchased from B. Schircks Laboratories (Jona, Switzerland). [ 3 H]NAAG is shipped in phosphate buffer, however phosphate inhibition of GCP II did not interfere with kinetic analysis at the concentration of [ 3 H]NAAG used. To exchange the buffer for inhibitor analysis and to purify N-acetyl-L-aspartyl-L- [3, H]glutamate (NEN Life Science Products), up to 250 l of 24 M [ 3 H]NAAG was applied to a 1-ml bed volume of anion exchange resin AG 1-X8 (Bio-Rad, Hercules, CA), washed with 3 ml of 1 M formic acid, and eluted in 3 ml of 7.5 M formic acid. The sample was lyophilized and resuspended in 3 ml of H 2 O and lyophilized two more times. The pellet was resuspended in 200 mM Tris, pH 9.5, and if necessary, the pH adjusted to 7.0 with NaOH.
Immunoblot Analysis. To normalize for the amount of enzyme used between wild type and mutants in the kinetic assays, the relative amount of GCP II protein was quantitated by immunoblotting (Western blot analysis). Cellular lysates were separated by 7% SDS-polyacrylamide gel electrophoresis, transferred to nitrocellulose in 10 mM 3-cyclohexylamino-1-propane sulfonic acid, pH 11, 1% methanol, and probed with the monoclonal antibody 7E11-C5 at 3 g/ml (a generous gift from Drs. Gerald Murphy and Alton Boynton) (Israeli et al., 1994) . The 7E11-C5 antibody recognizes the N terminus of GCP II (Troyer et al., 1995b) . Because no mutations were near this epitope, amino acid substitutions were not expected to interfere with binding of the antibody. Horseradish peroxide-conjugated sec- ondary antibody (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA) was used to visualize the complex in conjunction with the chemiluminescent substrate SuperSignal ULTRA (Pierce). Data were collected with a Fluor-S MultiImager (Bio-Rad) and analyzed by Multi-Analyst software (Bio-Rad). To test that the immunoblot was linear in the range of experimental samples, the intensities were measured as a function of time. The amount of GCP II protein is expressed per microgram of total protein loaded. For qualitative analysis, immunoblots were visualized using film autoradiography.
Deglycosylation of Native Protein. To characterize the two bands observed in the immunoblot of transiently expressed GCP II, samples were deglycosylated under denaturing conditions with peptide-N-glycosidase according to the manufacturer's recommended protocol (Oxford GlycoSciences, Inc., Bedford, MA) and probed with 7E11-C5 antibody in an immunoblot as described above.
Results
Substitutions to Putative Zinc Ligands. Based on amino acid sequence alignment to other cocatalytic zinc peptidases of the M28 family, the catalytic domain and potentially important functional groups have been identified in GCP II (Rawlings and Barrett, 1997) . Site-directed mutagenesis has been used to test the assignment of specific amino acid residues implicated in zinc and substrate binding. Single substitutions to putative zinc ligands resulted in a profound loss of enzyme activity (Table 3 ). The severe loss of activity in these mutants is not due to the inability of transfectants to express GCP II protein, as determined by immunoblot analysis (examples shown in Fig. 2A ). However, reduced expression was observed for some of these mutants ( Table 3 ). The only mutant in which kinetic parameters were obtainable was D387N, a substitution at the putative bridging ligand that resulted in both an increased K m value and a decreased V max when compared with wild type (Fig. 3 and Table 4 ). The profile of activity versus metal ion concentration did not change for the D387N and E424Q (see below) mutants when compared with wild-type enzyme, suggesting that these substitutions did not disrupt metal binding (data not shown).
Substitutions to Residues Next to Putative Zinc Ligands. Substitutions to residues next to each of the five putative zinc ligands were also targeted. These included Asp-379, Pro-388, Glu-424, Ser-454, and Tyr-552. The following results are shown in Tables 3 and 4 . 1) Conservative substitutions at Asp-379 resulted in no detectable enzyme activity (after a 16-h incubation) and in a reduced expression of protein, underscoring the importance of the structure in this region. In the Streptomyces and Vibrio aminopeptidases, the corresponding residue was hydrogen bonded to the nearby histidine zinc ligand. 2) Substitution of Pro-388 to Ala resulted in a large increase in K m . It has been noted in binuclear zinc metallopeptidases that a cis-peptide bond occurs near one of the zinc ligands (Table 1). 3) The E424Q mutant resulted in a reduced V max value along with an increase in K m (Fig. 3 and Table 4 ). A glutamate implicated in catalysis is typically found next to one of the zinc ligands in both biand mononuclear zinc metallopeptidases (Rowsell et al., 1997) . 4) The S454A mutant had a decrease in V max . 5) The Y552F mutant had an increased K m and decreased V max . In the Vibrio and Streptomyces aminopeptidases the corresponding positions (Ser-454 and Tyr-552) are implicated as comprising part of the substrate binding pocket indicating proximity to the active site.
Substitutions to Putative Substrate Ligands. In contrast to substitutions to putative zinc ligands, single substitutions to putative substrate ligands were less disruptive to enzyme activity so that kinetic parameters could be obtained for most of the mutants. For the positively charged residues implicated in determining substrate specificity, including Lys-500, conservative substitutions that exchanged Lys for Arg did not markedly alter the kinetic parameters (Table 4) . However, when the substitution introduced a large charge perturbation (e.g., Lys to Glu), the K m for substrate of these mutants increased greatly. This was seen for the R463I, R536E, and K545E mutants ( Table 4 , an example of which is shown in Fig. 3A ). Immunoblot analysis indicates that the expression of these mutants is like wild type except that the upper band is faint for the R463I mutant (data not shown). No activity was detected for the K500E mutant (after a 16-h incubation), and reduced expression was observed in an immunoblot ( Fig. 2A) . Little change in the kinetic parameters was seen for the K499E and S501A mutants, even though they are directly next to Lys-500, which has no activity when substituted to Glu. Very little activity was seen for the N519D mutant after a 16-h incubation, so kinetic parameters could not be obtained. Finally, the T538V mutant had a large increase in the K m parameter ( TABLE 1 Putative zinc ligands and nearby residues targeted for substitution in GCP II Amino acids targeted for substitution were based on comparison with the following proteins of known structure: aminopeptidases from S. griseus and V. proteolyticus, and carboxypeptidase G 2 , CPG2 (Greenblatt et al., 1997; Chevrier et al., 1994; Rowsell et al., 1997) . Interactions of residues with Zn 2ϩ , Hg 2ϩ , H 2 PO 4 Ϫ , and hydroxamate that were observed in the crystal structures are indicated under "Comments". Based on the alignment, certain predictions can be made: Asp-379 is proposed to hydrogen bond to the putative zinc ligand His-377. Asp-387 is the putative bridging ligand. Pro-388 is proposed to be involved in a cis-peptide bond with Asp-387. Glu-424 is predicted to be involved in catalysis. (Pinto et al., 1996) . The IC 50 was determined for pteroylpenta-␥-glutamate in the presence of [ 3 H]NAAG for some of the mutants (Table 5 ). An 8-and 9-fold increase was seen in the IC 50 for the R536E and K545E mutants, respectively (Table 5) , consistent with their increased K m for NAAG (Table 4 ). The Y552F mutant showed dramatic changes in the IC 50 for PMPA, phosphate, glutamate, and pteroylpenta-␥-glutamate (Table 6) , suggesting a role for this residue in binding these inhibitors and/or NAAG.
GCP II
Immunoblot Analysis. To determine whether mutant protein was expressed, immunoblot analysis was performed. Mutant protein was expressed even for those mutants that showed no activity ( Fig. 2A) . Two bands observed in the immunoblot suggest that two different species were present. One explanation for the two bands is differential glycosylation. To test this, the lysate from cells transfected with wildtype cDNA (i.e., expression of native enzyme) was deglycosylated under denaturing conditions and run on a gel for immunoblot analysis. One band was predominately seen at 84 kDa, consistent with the predicted size of the GCP II polypeptide (i.e., deglycosylated protein) (Fig. 2B) . The human prostate cancer cell line LNCaP overexpresses GCP II (Israeli et al., 1994) . The LNCaP cell lysates expressed one Amino acids proposed to make up part of the specificity pocket in GCP II are based on the corresponding residues observed in the crystal structure for the Vibrio aminopeptidase (Chevrier et al., 1994) . Assignment of residues in Streptomyces is based on the superimposition and amino acid sequence alignment to the Vibrio aminopeptidase (Greenblatt et al., 1997) . The carbonyl oxygen of Arg-202 in Streptomyces hydrogen bonds with the zinc bound H 2 PO 4 Ϫ . In contrast to putative zinc ligands and adjacent residues that are indicated in Table 1 7E11-C5 immunoreactive species that migrated at a position that is in between the two bands from the transfected samples. Upon deglycosylation this band migrated at the same position as the deglycosylated transfected sample (Fig. 2B) .
The migration pattern of the two bands around 100 kDa in the immunoblot gives an indication of the glycosylated state. A band at 84 kDa would indicate a deglycosylated form. None of the mutants showed a band around 84 kDa, suggesting that all of the mutants are glycosylated (Fig. 2A) . To test whether glycosylation may influence enzyme activity, the putative glycosylation site Asn-459, which is near the putative Zn ϩϩ ligand Asp-453, was substituted to Asp. The two bands observed in an immunoblot ran slightly faster than wild-type protein, indicating an alteration in the glycosylated state (data not shown). The N459D mutant also had slightly altered kinetic parameters (Table 4 ) and a 2-fold increase in the IC 50 for pteroylpenta-␥-glutamate (Table 5 ). In general, anomalous band migration (e.g., D387L in Fig. 2A ) in the immunoblot, indicated by italics in Tables 3 and 4 , correlated with no detectable activity, with the exception of N459D. For those mutants for which kinetic parameters were obtained, the two bands seen in the immunoblot migrated with wildtype protein, suggesting that glycosylation had not drastically changed and that the affect of the mutation was the result of the substitution and not due to a change in glycosylation.
Discussion
Site-directed mutagenesis has been performed in the human gene for GCP II to test assignments of specific amino acids implicated in metal ligand binding, substrate binding, and other structural and functional aspects of enzyme catalysis. Assignments of these residues are based on the amino acid sequence alignment of GCP II to low molecular weight aminopeptidases whose crystal structures have been determined (Chevrier et al., 1994; Rawlings and Barrett, 1997; Greenblatt et al., 1997) . These aminopeptidases from S. griseus and V. proteolyticus are cocatalytic zinc metallopeptidases that are members of the peptidase family M28. Zinc ligands are conserved between these aminopeptidases and GCP II (Table 1) . However, putative substrate ligands are not conserved (Table 2) , consistent with a difference in substrate specificity. All residues targeted for mutagenesis that resulted in altered kinetic parameters, including putative substrate ligands, are conserved among the human, rat, and pig.
Substitutions to Putative Zinc Ligands. Single substitutions have been designed at each of the five putative Zn ϩϩ ligands (Table 3) . A topological diagram, based on the Vibrio aminopeptidase structure, is shown in Fig. 4 summarizing the mutagenesis results and indicating the corresponding ligands in GCP II. In general, substitutions to putative zinc ligands are more disruptive to enzyme activity and stability as detected by immunoblot analysis than are substitutions to putative substrate ligands. It is not uncommon for apo-proteins to be less stable than their holoenzyme. For example, increased protease susceptibility was observed in the apoenzyme of a mutated zinc binding site of peptide deformylase from Escherichia coli (Meinnel et al., 1995) .
The only GCP II mutant in which substantial activity was observed is for the putative bridging ligand, D387N. The altered kinetic parameters for the D387N mutant suggest The potent inhibitor PMPA is a glutamate analog with a phosphate substitution at the amine position (Jackson et al., 1996) . Phosphate (H 2 PO 4 Ϫ) is a low potency inhibitor. Pteroylpenta-␥-glutamate (PPG) is also hydrolyzed by GCP II (Pinto et al., 1996) . Glutamate (Glu) is a product of NAAG hydrolysis. ␤-NAAG is a nonhydrolyzable NAAG analog. Conditions are described in the legend for Table 5 . Site-Directed Mutagenesis of Glutamate Carboxypeptidase II 183 that this important residue plays either an indirect or direct role in catalysis. Although there is as yet no direct evidence for the perturbation of metal coordination in mutants containing substitutions to putative metal ligands, the results are consistent with the observation that known zinc ligands are highly conserved in the sequence alignment of the peptidase family M28. Substitutions to Residues Next to Putative Zinc Ligands. Amino acid residues next to metal ligands can affect the local structure and/or function of the enzyme. In the crystal structures of the Streptomyces and Vibrio aminopeptidases, the corresponding Asp-379 is shown to hydrogen bond to His-377. There may be a requirement for the proper positioning or electronic interaction of His-377 such that substitution of Asp-379 to Glu or Asn dramatically perturbs the local structure and/or function (Table 3 ). This triad feature (e.g., Asp-His-Zn ϩϩ ) is also found in other proteases such as the mononuclear zinc site of thermolysin in which both zinc-associated histidines are also coordinated by either an Asn or Asp. It has been proposed that the active site of neutral endopeptidase (NEP) has a similar structure to thermolysin (Benchetrit et al., 1988) . A substitution similar to the present case in NEP also decreased enzyme activity in which the corresponding Asp of the triad (i.e., Asp-650) was mutated to Glu, Asn, or Ala, (Le Moual et al., 1994) .
A nonproline cis-peptide bond that involves the backbone of the bridging aspartic acid ligand is observed in the crystal structure of the Vibrio and Streptomyces aminopeptidases and carboxypeptidase G 2 . As pointed out by Rawlings and Barrett (1997) , a proline, which is more likely to accommodate a cis-peptide bond, is at this corresponding position in GCP II next to the putative bridging zinc ligand Asp-387. The large increase in K m (Ͼ3 M) for substitution to Ala suggests that Pro-388 plays an important structural role in the active site of GCP II that most likely affects substrate binding indirectly.
Substitution of Glu-424 to Gln resulted in a decrease in V max suggesting a role for this carboxylate in catalysis. In the Vibrio aminopeptidase, the corresponding glutamate (Glu-151) has been proposed to be a general base in the catalytic mechanism and has been shown to be involved in binding to the bridging H 2 O or phosphate or to a hydroxamate inhibitor (Table 1) (Chevrier et al., 1996) . In the mononuclear carboxypeptidase A and thermolysin, a glutamate residue, implicated in the catalytic mechanism, is in a HEXXH motif in which the Glu is the putative catalytic residue and the two His are Zn ϩϩ ligands. Substitutions of Glu to Asp or Gln in this motif in peptide deformylase and NEP resulted in decreased activity Meinnel et al., 1995) .
Both Ser-454 and Tyr-552 may comprise part of the substrate-binding site because their corresponding residues in the Vibrio aminopeptidase help define a specificity pocket. In addition, these amino acids are directly next to putative zinc ligands, and the corresponding Tyr-552 in the Streptomyces aminopeptidase has been shown in the crystal structure to hydrogen bond with phosphate that is bound between the two zinc ions. The reduced V max suggests that these residues, like Glu-424, are important for enzymatic activity. However, the corresponding Ser-454 and Tyr-552 are not conserved (Table  1) . These substitutions may indirectly perturb the local structure or reflect mechanistic differences unique to each particular peptidase. Interestingly, the large increase in the IC 50 for PMPA or phosphate in the presence of NAAG may indicate that the Tyr-552 hydroxyl is important for the binding of these inhibitors. PMPA is a glutamate analog with a phosphate substitution at the amine position (Jackson et al., 1996) . Tyr-552 may possibly bind to the phosphate functionality of PMPA because phosphate inhibition was also perturbed in the Y552F mutant.
Putative Substrate-Binding Determinants. Four positively charged residues in GCP II have been predicted by Rawlings and Barrett (1997) to be involved in the binding of the negatively charged substrates. The corresponding residues in the Vibrio aminopeptidase make up part of the hydrophobic substrate specificity pocket. The present data support the assignment of these specificity determinants. Because many residues are involved in substrate binding, it might be expected that any one residue would contribute only partially to the overall affinity for substrate. In this case, a single substitution would not be expected to eliminate binding. The data support this concept, because certain substitutions alter but do not abolish activity. Only when the substitution was a large charge perturbation, such as Lys to Glu, has a large change in K m been observed. The only prediction not substantiated was for Lys-499. However, this amino acid is not conserved in the rat or pig sequence (Bzdega et al., 1997; Halsted et al., 1998; Luthi-Carter et al., 1998) . Interestingly, there is another Lys conserved in the rat and pig sequences directly next to Lys-499 at position 500 wherein substitution to Glu resulted in a loss of enzyme activity. Location of these putative substrate binding residues is shown in Fig. 4 . An exchange of Lys and Arg did not seem to perturb substrate binding (Table 4) , supporting the role of the positively charged nature of these residues in binding. Altered binding of pteroylpenta-␥-glutamate by some of these mutants indicates that NAAG and folylpolyglutamate may share com- The predicted catalytic domain shown is from residues 287 to 587. Regions of secondary structure are shown when aligned to the Vibrio aminopeptidase. Arrows indicate ␤-sheets and cylinders ␣-helices. A summary of substitutions that resulted in altered enzyme activity is indicated: 1) The putative zinc ligands are circled with their corresponding positions indicated. 2) Neighboring residues to the putative zinc ligands are indicated in bold. 3) Positively charged residues thought to bind substrate are indicated in bold and a plus sign. 4) Two other residues implicated in substrate binding are Asn-519 and Thr-538. Asn-459 is one of three putative glycosylation sites located in the catalytic domain. mon binding determinants. Our data indicate that specific residues, including positively charged ones, influence substrate binding either directly or indirectly and are consistent with the model proposed by Rawlings and Barrett (1997) .
Identification of Important Structural and Functional Elements through Evolutionary Conservation. Important structural similarities are often identified by similarities between mammalian and bacterial proteins. Interesting examples for which mutagenesis studies have been conducted include both metabotropic and ionotropic glutamate receptors, such as the N-methyl-D-aspartate receptor in which similarities to bacterial amino acid binding proteins have been observed (O'Hara et al., 1993; Kuryatov et al., 1994; Stern-Bach et al., 1994; Paas et al., 1996) . As mentioned previously, structural similarities have been identified between NEP, a type II membrane zinc metallopeptidase, and the mononuclear zinc containing thermolysin (Benchetrit et al., 1988) . Mutagenesis analyses of NEP support assignments made from the sequence alignment even though little amino acid identity exists between the two sequences (Marie-Claire et al., 1997 and references therein). These studies, like the current one, suggest that the threedimensional structure of the mammalian proteins are similar to their bacterial counterparts and that structural and functional elements can be predicted based on these comparisons. Lastly, our data from the mutagenesis studies may provide useful information to aid in the design of pharmacologic reagents.
